Metagenomi Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Operating income | -$96.0M | -$88.9M | -$78.5M |
| Operating expenses | $121.2M | $141.2M | $123.2M |
| Cash from operations | -$88.9M | -$109.1M | -$91.4M |
| Capital expenditure | $574,000 | $3.1M | $9.8M |
| Free cash flow | -$89.5M | -$112.2M | -$101.2M |
| Impairments | — | $1.0M | $23,000 |
| Total assets | $221.1M | $324.6M | $364.8M |
| Total liabilities | $62.5M | $89.7M | $149.7M |
Shares outstanding 37.6M · Free float 71.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.